On an unseasonably warm day in late February, researchers at Kunming Medical University’s Experimental Animal Center in the far southwestern province of Yunnan injected a female crab-eating macaque with a speculative brand-new drug, code-named Rett001.

The drug’s core element is a particular gene, MECP2, framed in an adeno-associated infection (AAV). If the experiment works, the AAV will take its hereditary payload through the monkey’s back fluid straight to cells in the brain, where it will reproduce and change the malfunctioning copies being produced by the monkey’s body.

Countless miles away, neuroscientist Qiu Zilong kept an eye on the experiment from his workplace at Shanghai Jiao Tong University’s Songjiang Research Institute. Qiu wishes to begin medical trials on human topics as quickly as this fall, offered the drug is shown safe in primates, as he plays catch-up in the race to discover brand-new treatments for kids impacted by Rett syndrome, an extreme and extremely unusual hereditary neurological condition that happens practically solely in women. As soon as classified as an autism spectrum condition, Rett impacts roughly 1 in 10,000 ladies, triggering extensive disabilities that impact almost every element of a kid’s life: their capability to speak, stroll, consume, and even breathe.

There is presently no recognized remedy, though 2 brand-new gene treatment treatments have actually begun medical trials outside China. Qiu stresses about the sluggish approval procedure and high costs of foreign drugs in China. If he can guide Rett001 to market, it would not just use Chinese households a less expensive option however likewise bring closure to Qiu’s almost 20-year battle versus the condition.


Qiu was drawn to autism research study as a doctoral trainee in neurobiology at the Shanghai Institute of Biochemistry and Cell Biology, in part due to the fact that of the relative clearness of its causes. “Compared to other brain conditions, autism is a fairly clear clinical issue,” Qiu states. “Conditions like Alzheimer’s or anxiety typically have several causes, whereas the reason for autism is reasonably uncomplicated, typically including hereditary anomalies. We can recognize the particular hereditary cause of over 50% of autism clients in China.”

Qiu anticipated to continue that research study when he took a postdoctoral research study position at the University of California, San Diego in 2003. His coach, neuroscientist Anirvan Ghosh, who signed up with the UCSD professors the exact same year as Qiu, pressed him to likewise think about looking for moneying to study syndromes associated with autism. That’s how, in 2006, he satisfied Monica Coenraads, the co-founder and clinical director of the Rett Syndrome Research Foundation.

Coenraads ended up being included with Rett syndrome research study after her 2-year-old child was detected with the condition. In 1999, stimulated by doctor Huda Zoghbi’s groundbreaking finding that Rett was triggered by anomalies on the X chromosome within the MECP2 gene, she co-founded the RSRF to spark clinical interest and promote research study on the syndrome.

Qiu’s conference with Coenraads was the very first time he had actually become aware of Rett syndrome– which he calls a “extreme subtype of Autism spectrum condition”– however he required to investigating it practically right away. The condition, with its specific hereditary causes however no apparent option, resonated with his clinical perceptiveness, he states, and he used and got an RSRF research study grant the list below year.

In 2009, as China increase its push to tempt abroad academics back to the nation, Qiu took a position with the Center for Excellence in Brain Science and Intelligence Technology in Shanghai, where he continued his research study into autism and Rett syndrome. Because function, he dealt with 2 of the city’s biggest health centers– Xinhua and the Shanghai Mental Health Center– to develop China’s biggest autism gene sequencing database.

Qiu’s group has actually given that carried out hereditary sequencing on over 1,000 households and recognized 22 genes associated to autism, consisting of 9 that were not formerly understood. Qiu likewise discovered that the hereditary anomalies connected to autism in China vary considerably from those in Europe and the United States, which he tentatively recommended might be due to the nation’s relative hereditary homogeneity. And in 2016, his group released a paper in Nature that showed the abovementioned results of a modified MECP2 gene on crab-eating macaques, an advance that permitted researchers to study Rett syndrome in non-human primates.

Qiu was growing uneasy with a life of fundamental research study and progressively interested in the medical applications of his research study. “Sometimes, moms and dads of autistic kids would visit my workplace,” Qiu remembers. “These moms and dads were deeply encouraged to assist their kids. It harmed to describe to them that I was a fundamental scientist, not a doctor.”


Qiu credits his coach, Ghosh, as his design for how a researcher can effectively shift into pharmaceutical advancement. In 2011, quickly after Qiu went back to China, Ghosh amazed his coworkers at UCSD by stopping his task and taking a leading research study position at pharmaceutical company Roche.

“Anirvan’s choice sent out a motivating message: Be strong in pursuing what interests you,” Qiu states. “He made that choice when he was 45, around the very same age I was when I considered making a modification (in 2017).”

The genuine draw was the possibility to work with advanced innovations that had actually considerably reduced the course from standard research study to prospective treatment.

“Initially, I believed that illness connected to genes, like autism, had a lot of enigma,” Qiu states. “There was a great deal of argument, and it may take another 20 years to completely comprehend them. The development of CRISPR gene modifying innovation started producing incredible scientific outcomes within a couple of years,” he includes, referring to brand-new techniques that enable hereditary adjustment of living organisms. “So, scientists like me might all of a sudden begin taking a look at methods to equate our findings into useful options for clients.”

Qiu’s interest dovetailed perfectly with a push by the Chinese federal government to focus on brand-new sources of financial development, consisting of the pharmaceutical market. In 2022, the federal government of Shanghai’s rural Songjiang District teamed with the Shanghai Jiao Tong University School of Medicine to construct a brand-new neurological research study institute concentrated on used research study.

The institute’s director, Duan Shumin, a previous coworker of Qiu’s at the Center for Excellence, rapidly connected, and in early 2023, Qiu left the location where he had actually invested the previous 15 years for a brand-new task and a brand-new function: discovering a treatment for Rett syndrome.


Current clinical advances have actually opened brand-new possibilities for the treatment of a host of neurological conditions, from deep brain stimulation for Parkinson’s illness to brain implants targeting anxiety.

None of these approaches are reliable in autism clients.

“Autism is a brain-wide condition, not restricted to any particular area,” Qiu states. “Currently, gene treatment is the only technique that can efficiently deal with the whole brain and yield fairly great outcomes.”

In essence, gene treatment includes presenting genes into target cells, typically by utilizing adeno-associated infections as providers. While this has actually been shown safe in liver, muscle, and ocular tissue, straight utilizing it to deal with brain conditions stays unusual. The obstacle depends on providing replacement genes through the protective blood-brain barrier. Compounds administered orally or intravenously can not cross this barrier quickly, requiring clinicians to inject gene-carrying adenoviruses straight into the spine.

Qiu’s group begun by screening hereditary treatments targeting the MECP2 and MEF2C genes on mice, with favorable outcomes on social interaction and repeated habits deficits. Now they’re checking the efficiency of MECP2 interventions on monkeys, with an eye on showing the treatment’s security for usage in human beings.

In the meantime, Qiu is beginning to search for prospective research study individuals. “In theory, the more youthful the client, the much better the results of gene treatment,” he states. “Ideally, we would deal with babies or kids aged 1 or 2, as their brain advancement is most active. For security factors, we’re preparing to pick a little older kids for this trial.”

He’s eager to begin– and acutely conscious that China still lags in autism and Rett syndrome research study. 2 drugs have actually currently begun human trials outside China: TSHA-102, which was administered to an adult in Canada for the very first time last June, and NGN-401, which began pediatric trials in the United States last December. Still, he stays positive that his research study can have a favorable effect.

“Even if foreign nations effectively establish these drugs, they will unquestionably be excessively pricey and beyond the reach of common Chinese households,” Qiu states. From this point of view, having actually locally established drugs in China is essential. “Besides, who understands, possibly ours will be even much better.”

(Header image: Archv/VCG)

Learn more